FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| A Secondary Analysis of a Preliminary Contingency Management Intervention for Presurgical Cancer Patients: Evaluating Individual Participant Data. PMID 37156634 · Nicotine Tob Res · 2023-Aug-19 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| A novel super-enhancer-related gene signature predicts prognosis and immune microenvironment for breast cancer. PMID 37596527 · BMC Cancer · 2023-Aug-18 The study is a retrospective prognostic biomarker analysis and in vitro functional study, not a Phase III/IIIb or Phase II/III randomized controlled trial with a drug-containing intervention and a primary/key secondary time-to-event efficacy endpoint. The 'Randomized Controlled Trial' publication type is incorrect for this content. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A multicenter noninferior randomized controlled study comparing the efficacy of laparoscopic versus abdominal radical hysterectomy for cervical cancer (stage IB3 and IIA2): study protocol of the LAUNCH 3 trial. PMID 37592299 · Trials · 2023-Aug-18 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Relugolix combination therapy in European women with symptomatic uterine fibroids: a subgroup analysis from the randomized phase 3 LIBERTY pivotal trials. PMID 37634528 · Gynecol Endocrinol · 2023-Aug-17 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
B
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Safety and efficacy of precision hepatectomy in the treatment of primary liver cancer. PMID 37592238 · BMC Surg · 2023-Aug-17 The study is a randomized, oncology, human trial with original results, but it compares two surgical techniques and does not involve a drug intervention. Furthermore, the key efficacy outcomes (recurrence, mortality) are reported as rates at 2 years, not as time-to-event curves or hazard ratios, which are required for this adjudication. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Detection method has independent prognostic significance in the PLCO lung screening trial. PMID 37591907 · Sci Rep · 2023-Aug-17 While this is an original, randomized, phase III-level oncology study with human participants, it lacks a drug-containing intervention and a primary/key secondary time-to-event efficacy endpoint for a therapeutic agent. It is a prognostic analysis within a screening trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study. PMID 37587493 · Arthritis Res Ther · 2023-Aug-16 The study is a randomized Phase 3b trial of guselkumab in psoriatic arthritis, not an oncology study. While it is a drug-intervention RCT reporting original results, it does not have a time-to-event efficacy endpoint (OS, PFS, DFS, etc.) or any survival analysis (Kaplan-Meier, HR). |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Clinical Activity of Combined Telomerase Vaccination and Pembrolizumab in Advanced Melanoma: Results from a Phase I Trial. PMID 37378632 · Clin Cancer Res · 2023-Aug-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma. PMID 37265425 · Clin Cancer Res · 2023-Aug-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Obesity in adult acute myeloid leukemia is not associated with inferior response or survival even when dose capping anthracyclines: An ECOG-ACRIN analysis. PMID 37185873 · Cancer · 2023-Aug-15 The record is a secondary analysis of prognostic factors from two randomized trials. While it is oncology, human, randomized, drug-based, and reports time-to-event outcomes, it is not the primary report of the randomized trial results. Furthermore, the specific trial phase (III or II/III) is not explicitly confirmed in the provided metadata. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| FDA Approval Summary: Atezolizumab as Adjuvant Treatment following Surgical Resection and Platinum-Based Chemotherapy for Stage II to IIIA NSCLC. PMID 36951523 · Clin Cancer Res · 2023-Aug-15 The record is an original report of results from a randomized trial (IMpower010) in human oncology (NSCLC) with a drug intervention (atezolizumab) and a primary time-to-event endpoint (DFS). However, the explicit trial phase (Phase III, Phase II/III, etc.) is not established in the provided metadata (title, abstract, publication types, MeSH). The deterministic review signal 'phase3' is false. Since phase eligibility cannot be confirmed, is_eligible is set to null. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| [Analysis of prognostic factors of extranodal NK/T-cell lymphoma treated with pegaspargase/L-asparaginase: a multicenter retrospective study]. PMID 37803837 · Zhonghua Xue Ye Xue Za Zhi · 2023-Aug-14 The study is a retrospective prognostic factor analysis, not a prospective Phase III/IIIb or Phase II/III randomized trial. Although it includes randomized assignment for statistical validation and time-to-event data, it does not meet the core requirement of being a definitive phase trial report. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Rotational ThromboElastometry-guided blood component administration versus standard of care in patients with Cirrhosis and coagulopathy undergoing Invasive ProcEdures (RECIPE): study protocol for a randomised controlled trial. PMID 37568228 · Trials · 2023-Aug-11 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer patients undergoing mastectomy with one to two metastatic sentinel lymph nodes: sub-analysis of the SINODAR-ONE multicentre randomized clinical trial and reopening of enrolment. PMID 37471574 · Br J Surg · 2023-Aug-11 The record describes a randomized trial in human breast cancer with time-to-event efficacy endpoints (OS, RFS) and original results. However, the intervention is non-drug (surgical procedures: sentinel lymph node biopsy vs. axillary lymph node dissection), and the abstract explicitly identifies this as a 'sub-analysis' of a larger trial. The trial phase is not explicitly stated in the provided metadata to meet the Phase III/IIIb or Phase II/III requirement. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Exploring the safety and efficacy of phytomedicine Petiveria alliacea extract (Esperanza) in patients with metastatic gastrointestinal tumors and acute leukemias: study protocol for a phase Ib/randomized double blind phase II trial (PA001). PMID 37563608 · BMC Complement Med Ther · 2023-Aug-10 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Effects of early enteral nutrition on pancreatic fistula and long-term prognosis after distal pancreatectomy or enucleation of pancreatic tumours in a major academic university hospital in China: protocol for a single-centre randomised controlled trial. PMID 37562933 · BMJ Open · 2023-Aug-10 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer. PMID 37379158 · N Engl J Med · 2023-Aug-10 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Erratum: Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial. PMID 37364222 · J Clin Oncol · 2023-Aug-10 Record is an erratum notice for a Phase III trial (EMERALD) of elacestrant vs. standard endocrine therapy. While the trial itself meets oncology, human, randomized, phase 3, and drug intervention criteria, the provided metadata (an erratum with no abstract) lacks explicit information about a primary time-to-event endpoint (e.g., OS, PFS) or Kaplan-Meier results. Therefore, the time_to_event criterion cannot be established from this record alone. The report_type is set to 'other' as an erratum does not fit the primary/interim/final/subgroup etc. categories for trial results. |
H
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Erratum: Postoperative Adjuvant Anastrozole for 10 or 5 Years in Patients With Hormone Receptor-Positive Breast Cancer: AERAS, a Randomized Multicenter Open-Label Phase III Trial. PMID 37364217 · J Clin Oncol · 2023-Aug-10 This is a published erratum for an original Phase III trial. The metadata does not confirm a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, HR) or a drug intervention in this specific erratum record. An erratum is not a primary result report. |
H
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401. PMID 37307514 · J Clin Oncol · 2023-Aug-10 The study is a single-arm Phase IIIb oncology trial with drug intervention and OS as a secondary endpoint, but it is not randomized, which is a core eligibility criterion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A Machine Learning-Based Model to Predict In-Hospital Mortality of Lung Cancer Patients: A Population-Based Study of 523,959 Cases. PMID 37622839 · Adv Respir Med · 2023-Aug-09 The study is a predictive model for in-hospital mortality in lung cancer patients using retrospective data. It does not report on a time-to-event efficacy endpoint (like OS, PFS) from a Phase III/IIIb or Phase II/III randomized drug trial. The publication type 'Randomized Controlled Trial' appears to be a misclassification in the metadata, as the methods describe data splitting for model training/validation, not a comparative clinical trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Circulating T cell profiles associate with enterotype signatures underlying hematological malignancy relapses. PMID 37463582 · Cell Host Microbe · 2023-Aug-09 While the study is a randomized controlled trial in human oncology (hematological malignancies) with a drug intervention (azithromycin), it does not report a primary or key secondary time-to-event efficacy endpoint (like OS, PFS, DFS) as a result of the randomized comparison. The analysis focuses on gut microbiome enterotypes, immune cell profiles, and their association with relapse, not on standard time-to-event outcomes. Therefore, it does not meet the core requirement for a time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Total neoadjuvant therapy with short-course radiotherapy Versus long-course neoadjuvant chemoradiotherapy in Locally Advanced Rectal cancer, Korean trial (TV-LARK trial): study protocol of a multicentre randomized controlled trial. PMID 37553666 · BMC Cancer · 2023-Aug-08 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Fibrin-based haemostatic agents for reducing blood loss in adult liver resection. PMID 37551841 · Cochrane Database Syst Rev · 2023-Aug-08 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Target trial emulation to assess real-world efficacy in the Epidemiological Strategy and Medical Economics metastatic breast cancer cohort. PMID 37220893 · J Natl Cancer Inst · 2023-Aug-08 This record is an observational real-world effectiveness analysis (target trial emulation) of a retrospective cohort, not an original formal-result report of a randomized Phase III trial. It does not meet the 'original_result' or 'randomized' criteria for inclusion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A fixed-duration immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trial. PMID 37026799 · Blood Adv · 2023-Aug-08 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Cancer-Related Dysfunctional Beliefs About Sleep Mediate the Influence of Sleep Disturbance on Fear of Progression Among Patients With Surgically Resected Lung Cancer. PMID 37550804 · J Korean Med Sci · 2023-Aug-07 The record is a randomized controlled trial in oncology but does not meet the core eligibility criteria: it lacks a drug intervention and a time-to-event efficacy endpoint. The study evaluates a digital healthcare application for psychological outcomes, not a drug for cancer survival or progression. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The KORE-INNOVATION trial, a prospective controlled multi-site clinical study to implement and assess the effects of an innovative peri-operative care pathway for patients with ovarian cancer: rationale, methods and trial design. PMID 37208019 · Int J Gynecol Cancer · 2023-Aug-07 The record is a protocol for a non-randomized, controlled clinical study in ovarian cancer patients. It lacks all key eligibility criteria: it is not randomized, does not involve a drug intervention (focuses on pre-habilitation and ERAS), does not have a time-to-event efficacy endpoint (primary endpoint is post-operative complications), and is not a definitive-phase trial. It is a protocol without results. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Interstitial lung disease in patients treated with poly (ADP-ribose) polymerase inhibitors (PARPi): analysis of results from clinical trials and the FDA Adverse Events Reporting System database. PMID 37164363 · Int J Gynecol Cancer · 2023-Aug-07 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Randomised phase II trial of trifluridine/tipiracil (FTD/TPI) plus ramucirumab (RAM) versus trifluridine/tipiracil for previously treated patients with advanced gastric or esophagogastric junction adenocarcinoma (RETRIEVE study, WJOG15822G). PMID 37543568 · BMC Cancer · 2023-Aug-05 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| WISER Survivor Trial: Combined Effect of Exercise and Weight Loss Interventions on Adiponectin and Leptin Levels in Breast Cancer Survivors with Overweight or Obesity. PMID 37571390 · Nutrients · 2023-Aug-04 The trial is randomized, oncology-focused, and reports original results, but it lacks a drug intervention and a time-to-event primary endpoint. The endpoint is a biomarker change, not a survival or progression outcome. Phase information is also not provided. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| [18F]-fluoroethyl-L-tyrosine (FET) in glioblastoma (FIG) TROG 18.06 study: protocol for a prospective, multicentre PET/CT trial. PMID 37541751 · BMJ Open · 2023-Aug-04 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Predicting BRAFV600E mutations in papillary thyroid carcinoma using six machine learning algorithms based on ultrasound elastography. PMID 37537230 · Sci Rep · 2023-Aug-03 The study is an oncology diagnostic/predictive analysis for BRAF mutation in thyroid cancer using machine learning on ultrasound features. It is randomized (for data splitting) and human, but it is not a drug intervention trial, lacks a specified Phase III/IIIb or Phase II/III status, and does not report a time-to-event efficacy endpoint (e.g., OS, PFS). It reports diagnostic performance metrics (AUC, accuracy, etc.). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Duration of Adjunctive Antidepressant Maintenance in Bipolar I Depression. PMID 37530824 · N Engl J Med · 2023-Aug-03 The study is a randomized trial with a time-to-event primary endpoint and drug intervention, but it focuses on bipolar I disorder, which is not a malignant neoplasm (cancer). The title, abstract, and MeSH terms confirm the subject is psychiatric, not oncology. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Olanzapine With or Without Fosaprepitant for Preventing Chemotherapy Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy: A Phase III Randomized, Double-Blind, Placebo-Controlled Trial (ALLIANCE A221602). PMID 37284847 · Oncologist · 2023-Aug-03 The study is a randomized Phase III trial in oncology patients with a drug intervention, but the primary endpoint is a binary proportion (complete control of nausea), not a time-to-event outcome as required for the cohort. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations. PMID 37172204 · Blood · 2023-Aug-03 While the record is from a Phase III randomized trial with drug intervention and time-to-event endpoints, it is a secondary/biomarker analysis focused on prognostic factors (karyotype complexity) within the trial, not the primary trial report evaluating the efficacy of the venetoclax combinations. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A 6-Week Program to Strengthen Resiliency Among Women With Metastatic Cancer: A Randomized Clinical Trial. PMID 37104871 · Oncologist · 2023-Aug-03 This is a randomized trial in humans with metastatic cancer, but it evaluates a non-drug psychoeducational intervention (GRACE program) for spiritual well-being and quality of life, not a drug-containing intervention. It lacks a time-to-event efficacy endpoint (OS, PFS, etc.) and does not specify a trial phase. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Effect of Vitamin D Supplements on Relapse or Death in a p53-Immunoreactive Subgroup With Digestive Tract Cancer: Post Hoc Analysis of the AMATERASU Randomized Clinical Trial. PMID 37606927 · JAMA Netw Open · 2023-Aug-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Effect of Exercise on Chemotherapy-Induced Peripheral Neuropathy Among Patients Treated for Ovarian Cancer: A Secondary Analysis of a Randomized Clinical Trial. PMID 37526937 · JAMA Netw Open · 2023-Aug-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
B
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Radiotherapy Use and Incidence of Locoregional Recurrence in Patients With Favorable-Risk, Node-Positive Breast Cancer Enrolled in the SWOG S1007 Trial. PMID 37410451 · JAMA Oncol · 2023-Aug-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| A review of the clinical experience with CMN-001, a tumor RNA loaded dendritic cell immunotherapy for the treatment of metastatic renal cell carcinoma. PMID 37387210 · Hum Vaccin Immunother · 2023-Aug-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Safety and Efficacy of ApTOLL in Patients With Ischemic Stroke Undergoing Endovascular Treatment: A Phase 1/2 Randomized Clinical Trial. PMID 37338893 · JAMA Neurol · 2023-Aug-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Neoadjuvant immunochemotherapy for locally advanced resectable oral squamous cell carcinoma: a prospective single-arm trial (Illuminate Trial). PMID 37288582 · Int J Surg · 2023-Aug-01 The record is a prospective single-arm trial (non-randomized) with primary endpoints of safety and major pathological response (MPR), not a randomized Phase III trial with a primary time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Camrelizumab Plus Apatinib and Temozolomide as First-Line Treatment in Patients With Advanced Acral Melanoma: The CAP 03 Phase 2 Nonrandomized Clinical Trial. PMID 37261804 · JAMA Oncol · 2023-Aug-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Short-term and long-term effect of nutrition intervention in the Linxian Dysplasia Nutrition Intervention Trial and the reason for disappearance of the intervention effect: A cohort study. PMID 37243894 · Cancer · 2023-Aug-01 The study is a randomized oncology trial with time-to-event endpoints, but it is ineligible because the intervention is a non-drug nutritional supplement and the trial phase is not established as Phase III/IIIb or Phase II/III. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A Phase 1/2 Multicenter Randomized Trial of Local Ablation plus Toripalimab versus Toripalimab Alone for Previously Treated Unresectable Hepatocellular Carcinoma. PMID 37223896 · Clin Cancer Res · 2023-Aug-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Maveropepimut-S, a DPX-Based Immune-Educating Therapy, Shows Promising and Durable Clinical Benefit in Patients with Recurrent Ovarian Cancer, a Phase II Trial. PMID 37126016 · Clin Cancer Res · 2023-Aug-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Erratum: Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial. PMID 37104731 · J Clin Oncol · 2023-Aug-01 This is a published erratum for the ADAURA trial, which is an oncology, human, randomized, Phase III trial of a drug intervention (osimertinib). However, as an erratum, it is not an original formal result report and does not contain primary or secondary time-to-event efficacy endpoint results (OS, PFS, etc.). |
H
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Endosonography With or Without Confirmatory Mediastinoscopy for Resectable Lung Cancer: A Randomized Clinical Trial. PMID 37018653 · J Clin Oncol · 2023-Aug-01 The trial is a randomized, oncology, human study with original results, but it is not eligible because: 1) It does not involve a drug-containing intervention (intervention is a surgical procedure: mediastinoscopy). 2) It lacks a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR); the primary endpoint is the rate of unforeseen N2 disease, a binary diagnostic outcome. 3) It is not a Phase III/IIIb or Phase II/III trial (phase is not specified, but the design is a noninferiority trial comparing surgical strategies, not drug efficacy). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A Personalized Clinical Dynamic Prediction Model to Characterize Prognosis for Patients With Localized Prostate Cancer: Analysis of the CHHiP Phase 3 Trial. PMID 36822374 · Int J Radiat Oncol Biol Phys · 2023-Aug-01 The report is from a Phase 3 randomized trial with a time-to-event efficacy endpoint, but the intervention (moderately hypofractionated radiation therapy) is not drug-containing. The study also represents a secondary, predictive modeling analysis of the trial data, not the primary efficacy report. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |